Program for the Development of an Early Clinical Trial Infrastructure in Pediatric Oncology

Call for Applications

Progress in diagnosis and therapy has led to a significant increase in survival rates and quality of life of pediatric cancer patients in the past decades. It is mandatory to also accelerate this favorable trend for pediatric patients with poor prognostic or relapsed and refractory cancers and to provide them with access to new drugs through a better infrastructure for early (Phase I and Phase II) clinical trials.

As the major German cancer charity, the German Cancer Aid aims to support the further development of pediatric cancer centers and their recruitment networks in Germany that have already achieved a high standard of research and clinical care and that are willing to develop and implement innovative concepts for the efficient conduct of early clinical trials. In order to contribute to the development of a limited number of pediatric cancer centers of excellence in this field, we have launched this new program to set nationwide standards for the treatment of pediatric patients in early clinical trials and for strengthening the infrastructures supporting these.

German Cancer Aid is inviting for a first round of applications. In this phase, up to 3 centers/networks can be supported, each with 500,000 Euros per year over a period of five years. Financial support must be used for the strengthening of early clinical trial infrastructures and their regional networks, and not for specific research projects or clinical care.

Centers that wish to participate in this program are subject to a competitive selection process. In order to secure uniform structures and quality standards, applications submitted will be judged according to a number of defined criteria.

The evaluation will be carried out by an international panel of experts. Applications must therefore be written in English.

Please notify the German Cancer Aid of your intent to submit an application.


Subsequent full application deadline: September 30, 2020.